Literature DB >> 28505221

Combining PI3K and PARP inhibitors for breast and ovarian cancer treatment.

R Condorelli1, F André1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28505221     DOI： 10.1093/annonc/mdx218

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment.

Authors:  Hanjiao Qin; Linlin Liu; Shu Sun; Dan Zhang; Jiyao Sheng; Bingjin Li; Wei Yang
Journal:  PeerJ       Date:  2018-06-19       Impact factor: 2.984

Review 2.  Efficacy of PI3K inhibitors in advanced breast cancer.

Authors:  B Verret; J Cortes; T Bachelot; F Andre; M Arnedos
Journal:  Ann Oncol       Date:  2019-12-01       Impact factor: 32.976

3.  ZSTK474 Sensitizes Glioblastoma to Temozolomide by Blocking Homologous Recombination Repair.

Authors:  Wenhui Jiao; Shan Zhu; Jingrong Shao; Xiaoliang Zhang; Yanglu Xu; Yixuan Zhang; Ran Wang; Yuxu Zhong; Dexin Kong
Journal:  Biomed Res Int       Date:  2022-07-13       Impact factor: 3.246
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.